AI Engines For more Details: Perplexity Kagi Labs You
Probiotic Potential: Leuconostoc cremoris is considered a probiotic bacterium, meaning it has the potential to confer health benefits when consumed in adequate amounts. Probiotics are known to contribute to the balance of the gut microbiota, which plays a crucial role in digestive health, nutrient absorption, and immune function.
Digestive Health: Probiotic bacteria like Leuconostoc cremoris may help maintain gastrointestinal health by promoting the growth of beneficial bacteria in the gut and inhibiting the growth of harmful pathogens. This can contribute to improved digestion, reduced symptoms of digestive disorders such as irritable bowel syndrome (IBS), and enhanced bowel regularity.
Immune Modulation: Some research suggests that certain strains of lactic acid bacteria, including Leuconostoc cremoris, may have immunomodulatory effects, meaning they can modulate or regulate the immune system. By interacting with immune cells in the gut-associated lymphoid tissue (GALT), probiotics may help regulate immune responses, reduce inflammation, and enhance immune function.
Antimicrobial Properties: Lactic acid bacteria produce various antimicrobial compounds, such as organic acids and bacteriocins, that can inhibit the growth of pathogenic bacteria and fungi. These antimicrobial properties may help protect against infections and maintain microbial balance in the gut.
Nutrient Synthesis and Absorption: Some strains of lactic acid bacteria, including Leuconostoc cremoris, are capable of synthesizing certain vitamins and enhancing the absorption of nutrients in the intestines. This can contribute to overall nutritional status and support various physiological functions in the body.
Allergy and Atopic Disease Prevention: Emerging evidence suggests that early exposure to certain probiotic bacteria, including Leuconostoc cremoris, during infancy may help reduce the risk of developing allergic conditions such as eczema, asthma, and allergic rhinitis. Probiotics may exert their protective effects by modulating the immune system and promoting immune tolerance.
Rank | Probiotic | Impact |
---|---|---|
genus | Pediococcus | Increases |
species | Bifidobacterium adolescentis | Increases |
species | Bifidobacterium bifidum | Increases |
species | Bifidobacterium breve | Increases |
species | Bifidobacterium catenulatum | Increases |
species | Bifidobacterium longum | Increases |
species | Bifidobacterium pseudocatenulatum | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.8 | 0.8 | |
ADHD | 0.2 | 1 | -4 |
Allergic Rhinitis (Hay Fever) | 1.4 | 1.4 | |
Allergies | 1 | 0.6 | 0.67 |
Allergy to milk products | 0.6 | 0.6 | |
Alzheimer's disease | 1.6 | 0.6 | 1.67 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | -0.8 | |
Ankylosing spondylitis | 0.2 | 0.6 | -2 |
Asthma | 0.6 | 0.6 | 0 |
Atherosclerosis | 0.8 | -0.8 | |
Atrial fibrillation | 0.6 | 0.8 | -0.33 |
Autism | 1.4 | 1.4 | 0 |
Bipolar Disorder | 0.2 | -0.2 | |
Brain Trauma | 0.2 | 0.6 | -2 |
Carcinoma | 0.6 | 0.6 | 0 |
Celiac Disease | 1.2 | 0.4 | 2 |
Cerebral Palsy | 0.6 | -0.6 | |
Chronic Fatigue Syndrome | 0.8 | 0.8 | 0 |
Chronic Kidney Disease | 0.2 | 0.2 | 0 |
Colorectal Cancer | 0.6 | 0.6 | 0 |
Coronary artery disease | 0.2 | -0.2 | |
COVID-19 | 1.4 | 1.4 | 0 |
Crohn's Disease | 0.8 | 1 | -0.25 |
cystic fibrosis | 0.6 | 0.6 | |
Depression | 1.8 | 2.4 | -0.33 |
Dermatomyositis | 0.6 | 0.6 | |
Eczema | 1.2 | 1.2 | |
Endometriosis | 0.8 | 0.6 | 0.33 |
Epilepsy | 0.8 | 0.6 | 0.33 |
Fibromyalgia | 0.8 | 0.8 | |
Functional constipation / chronic idiopathic constipation | 0.8 | 0.8 | 0 |
gallstone disease (gsd) | 0.6 | 0.6 | 0 |
Generalized anxiety disorder | 0.8 | 0.8 | |
Graves' disease | 1 | -1 | |
Hashimoto's thyroiditis | 1.2 | 0.6 | 1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.6 | -0.6 | |
hyperglycemia | 1 | 1 | |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.6 | 0.33 |
hypertension (High Blood Pressure | 0.8 | 1 | -0.25 |
Hypothyroidism | 0.6 | 0.6 | |
Hypoxia | 0.2 | -0.2 | |
IgA nephropathy (IgAN) | 0.8 | 0.8 | |
Inflammatory Bowel Disease | 1 | 0.8 | 0.25 |
Insomnia | 0.2 | -0.2 | |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 1 | 0.8 | 0.25 |
Liver Cirrhosis | 1 | 0.8 | 0.25 |
Long COVID | 1.6 | 1.8 | -0.13 |
ME/CFS with IBS | 0.6 | 0.6 | |
ME/CFS without IBS | 0.6 | 0.6 | |
Menopause | 0.2 | 0.4 | -1 |
Metabolic Syndrome | 2 | 1.2 | 0.67 |
Mood Disorders | 1.8 | 2.4 | -0.33 |
multiple chemical sensitivity [MCS] | 0.2 | -0.2 | |
Multiple Sclerosis | 0.2 | 1 | -4 |
Multiple system atrophy (MSA) | 0.8 | 0.2 | 3 |
Neuropathy (all types) | 0.2 | -0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 0.6 | 1 |
NonCeliac Gluten Sensitivity | 0.6 | 0.6 | |
Obesity | 0.8 | 0.8 | 0 |
obsessive-compulsive disorder | 1 | 1 | |
Osteoarthritis | 0.2 | 0.2 | |
Osteoporosis | 0.2 | 0.2 | 0 |
Parkinson's Disease | 0.4 | 1.6 | -3 |
Polycystic ovary syndrome | 0.6 | 0.2 | 2 |
Postural orthostatic tachycardia syndrome | 0.6 | 0.6 | |
Premenstrual dysphoric disorder | 0.6 | -0.6 | |
Psoriasis | 0.8 | -0.8 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 1.4 | 0 |
Rosacea | 0.2 | 0.6 | -2 |
Schizophrenia | 0.6 | 1.2 | -1 |
Sjögren syndrome | 0.8 | 0.8 | |
Sleep Apnea | 0.6 | -0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
Stress / posttraumatic stress disorder | 0.6 | 0.8 | -0.33 |
Systemic Lupus Erythematosus | 1.4 | 0.2 | 6 |
Tic Disorder | 0.6 | 0.6 | |
Tourette syndrome | 0.2 | 0.2 | |
Type 1 Diabetes | 0.6 | 0.6 | |
Type 2 Diabetes | 1.4 | 1.2 | 0.17 |
Ulcerative colitis | 0.8 | 2 | -1.5 |
Unhealthy Ageing | 0.6 | 0.2 | 2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.